Table 3.
Additional reproducibility characteristics
| Characteristics | Variables |
|---|---|
| n (%) | |
| Type of study (n = 295) | |
| No empirical | 102 (34.6) |
| Meta-analysis | 4 (1.4) |
| Commentary with analysis | 1 (0.3) |
| Clinical trial | 17 (5.8) |
| Case study | 18 (6.1) |
| Case series | 3 (1.0) |
| Cohort | 46 (15.6) |
| Chart review | 16 (5.4) |
| Case control | 4 (1.4) |
| Data survey | 8 (2.7) |
| Laboratory | 46 (15.6) |
| Multiple | 1 (0.3) |
| Othera | 29 (9.8) |
| Material availability statement (n = 26) | |
| Personal or institutional | 5 (19.2) |
| Hosted by the journal | 18 (69.2) |
| Online third party | 1 (3.9) |
| On request | 2 (7.7) |
| Material was downloaded and accessible | 17 (65.4) |
| Material could not be downloaded and was not accessible | 9 (34.6) |
| Data availability statement (n = 41) | |
| Personal or institutional | 4 (9.8) |
| Supplementary information hosted by the journal | 31 (75.6) |
| Online third party | 0 (0.0) |
| On request | 6 (14.6) |
| Data could be accessed and downloaded | 31 (75.6) |
| Data could not be accessed and downloaded | 10 (24.4) |
| Documented data with all raw material (n = 31) | |
| Data files clearly documented | 31 (100.0) |
| Data files not clearly documented | 0 (0.0) |
| Data files contain all raw data used for study conduction | 11 (35.5) |
| Data files do not contain all raw data used for study conduction | 20 (64.5) |
| Preregistration statement listed (n = 8) | |
| Preregistration could be accessed | 7 (87.5) |
| Preregistration could not be accessed | 1 (12.5) |
| Preregistered on clinicaltrials.gov | 5 (62.5) |
| Otherb | 3 (37.5) |
| Documented within preregistration (n = 8) | |
| Hypothesis was included and documented within the preregistration | 2 (25.0) |
| Methods was included and documented within the preregistration | 7 (87.5) |
| Analysis plan was included and documented within the preregistration | 0 (0.0) |
| Protocol available (n = 4) | |
| Hypothesis was included within the protocol | 0 (0.0) |
| Methods was included within the protocol | 0 (0.0) |
| Analysis plan was included within the protocol | 0 (0.0) |
| Analysis script available (n = 4) | |
| Personal or institutional | 0 (0.0) |
| Supplementary information hosted by the journal | 4 (100.0) |
| Online third party | 0 (0.0) |
| On request | 0 (0.0) |
ISRCTN, International Standard Randomised Controlled Trial Number.
a
Includes cross-sectional (n = 18), secondary analysis (n = 11).
b
Includes Australian New Zealand Clinical Trials Registry (n = 1), Iranian Registry of Clinical Trials (n = 1), ISRCTN Registry (n = 1).